Nevro Corp. announced the Company will be participating in the Morgan Stanley 17th Annual Healthcare Conference in New York City.
REDWOOD CITY, Calif., Aug. 23, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Morgan Stanley 17th Annual Healthcare Conference in New York City. Nevro Chairman, CEO and President D. Keith Grossman is scheduled to present on Monday, September 9, 2019 at 2:50 pm Eastern Time.
A live webcast of the presentation, as well as an archived recording, will be available on the “Investors” section of the Company’s website at www.nevro.com.
About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only SCS systems that deliver Nevro’s proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
Investor Relations
Juliet Cunningham
Vice President, Investor Relations
650-433-3247
ir@nevro.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-morgan-stanley-17th-annual-healthcare-conference-300906236.html
SOURCE Nevro Corp.
Company Codes: NYSE:NVRO
